摘要
随着重组人类促红细胞生成素(rhEPO)的问世及临床应用,为肿瘤相关性贫血的治疗提供了一条新途径。目前的临床研究证实了rhEPO作为输血的替代疗法对肿瘤相关性贫血治疗的有效性和安全性,但是人们却很少注意到rhEPO是否对肿瘤细胞本身的生物学特性产生一定影响,这直接关系到其在治疗肿瘤相关性贫血中的价值,因此,rhEPO对肿瘤细胞有无增生作用目前已成为关注的焦点。
Along with the appearance and clinical use of rhEPO, a new approach has improved the treatment to tumor associated anaemia. At present the chnical research confirmed the security and effectiveness of treating tumor related anaemia, but the effect of rhEPO was not aware of the generation of tumor cells. It effects the treatable value of rhEPO on tumor related anaemia. So the effect of rhEPO on tumor associated anaemia has received great attention.
出处
《白血病.淋巴瘤》
CAS
2008年第4期309-312,共4页
Journal of Leukemia & Lymphoma